Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial

Clinical and Translational Radiation Oncology(2022)10.1016/j.ctro.2022.08.013Source: DataRank Database

Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial is a research paper published in Clinical and Translational Radiation Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 6 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access6 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.34)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Kiran Prabhu,William F. Hartsell ORCID,T.A. DeWees ORCID,Christopher Sinesi,Carlos Vargas ORCID

Live enrichment

PubMed:36093343 PMC:PMC9450061 OpenAlex:https://openalex.org/W4293393036

National Cancer Institute

Grant: 1/1/19 – 12/31/23

National Cancer Institute

Grant: P30-CA008748

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

National Institutes of Health

FWCI

0.34

Citation Percentile

0.5%

Citation Trend

2021

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttp://www.ctro.science/article/S2405630822000751/pdf

publisherhttp://www.ctro.science/article/S2405630822000751/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2405630822000751?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405630822000751?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ctro.2022.08.013

Fields of Study

Breast Cancer Treatment StudiesRadiation Therapy and DosimetryMultiple and Secondary Primary Cancers03 medical and health sciences0302 clinical medicine

Keywords

MedicineBreast cancerProton therapyRadiation therapyOncologyStage (stratigraphy)Internal medicineProspective cohort studyMulticenter trialNuclear medicineGynecologyCancerRandomized controlled trialMulticenter studyOutcomesBreast Conservation TherapyPartial Breast IrradiationMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensOriginal Research ArticleRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)